<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01894295</url>
  </required_header>
  <id_info>
    <org_study_id>91-03-27-18831</org_study_id>
    <nct_id>NCT01894295</nct_id>
  </id_info>
  <brief_title>Assessment Vitamin D Analogues Intake Pathways on the Proteins Which Involved in Metabolic Rate in Obese Subjects</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tehran University of Medical Sciences</source>
  <brief_summary>
    <textblock>
      The aim of this double blind clinical trial study is to investigate whether alphacalcidol
      treatment in obese subjects can affect the resting metabolic rate. Moreover, the
      investigators will evaluate the pathways of Nesfatin-1, Peroxisome proliferator-activated
      receptor gamma (PPARγ) and eroxisome proliferator-activated receptor- coactivator-1 α (PGC1α)
      protein which may lead to change in metabic rate following treatment with either
      alphacalcidol or placebo.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Resting Metabolic Rate</measure>
    <time_frame>Change from baseline to 8 weeks</time_frame>
    <description>Measurement by indirect calorimetry.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of Nesfatin-1, PPARγ and PGC1α protein levels</measure>
    <time_frame>Change from baseline to 8 weeks</time_frame>
    <description>Measurement by ELISA kit</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change of ACS and FASN Enzymes</measure>
    <time_frame>Change from baseline to 8 weeks</time_frame>
    <description>Measurement by ELISA kit</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Vitamin D analogue</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1-α hydroxyvitamin D3; dose 0.25, 0.5 and 1 microgram.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Corn oil pearl Capsules 1 gram</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Corn oil pearl Capsules 1 gram; were given to the intervention group once a day for 8 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>corn oil capsule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D analogue</intervention_name>
    <description>1-α hydroxyvitamin D3 dose 0.25, 0.5 and 1 microgram were given to the intervention group once a day for 8 weeks</description>
    <arm_group_label>Vitamin D analogue</arm_group_label>
    <other_name>1-α hydroxyvitamin D3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Age 22-52 years Body mass index equal or more than 30

        Exclusion Criteria:

        Acute or chronic inflammatory disease History of hypertension Alcohol or drug abuse History
        of any condition affecting inflammatory markers Thyroid diseases Malignancies Current
        smoking Diabetes mellitus Sustained hypertension Heart failure Acute or chronic infections
        Hepatic or renal diseases Use of PPARγ agonist drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>52 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mahmoud Jalali, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Tehran University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Khadijeh Mirzaei, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tehran University of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mahmoud Jalali, Phd</last_name>
    <phone>+982188954911</phone>
    <email>jalalimahmoud@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Khadijeh Mirzaei, MS</last_name>
    <phone>+989124379670</phone>
    <email>mina_mirzaei101@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>TehranUMS</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mahmoud Jalali, PhD</last_name>
      <email>jalalimahmoud@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Khadijeh Mirzaei, MS</last_name>
      <email>mina_mirzaei101@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 3, 2013</study_first_submitted>
  <study_first_submitted_qc>July 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2013</study_first_posted>
  <last_update_submitted>July 9, 2013</last_update_submitted>
  <last_update_submitted_qc>July 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vitamin D analogues</keyword>
  <keyword>Resting Metabolic rate</keyword>
  <keyword>obesity</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Hydroxycholecalciferols</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

